---
document_datetime: 2024-05-07 12:17:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_en.pdf
document_name: vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_en.pdf
version: success
processing_time: 0.8229797
conversion_datetime: 2025-12-22 21:10:54.656984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form      | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size                      |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------|---------------------------|--------------------------------|
| EU/1/21/1529/002 | Vaxzevria         | --1        | Suspension for injection | Intramuscular use         | Vial (glass)          | 5 ml (10 doses of 0.5 ml) | 10 multidose vials (100 doses) |

<!-- image -->

1 One dose (0.5 mL) contains: Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)*, not less than 2.5 Ã— 10 8 infectious units (Inf.U) * Produced in genetically modified human embryonic kidney (HEK) 293 cells and by recombinant DNA technology. Medicinal product no longer authorised